Immunocore to Present at Upcoming Investor Conferences
Immunocore to Present at Upcoming Investor Conferences
The presentations will be webcast live and can be accessed by visiting 'Events & Presentations', under 'Events', via the 'Investors' section of Immunocore's website at . Following the event, a replay of the presentations will be made available for a limited time.(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, 8 November 2024) Immunocore Holdings plc (Nasdaq: IMCR) ("Immunocore" or the "Company"), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced that management will participate in the following investor conferences in November.
(英國牛津郡，賓夕法尼亞康肖霍肯，美國蓋瑟斯伯格，馬里蘭州，2024年11月8日) 愛文思控股有限公司（納斯達克股票代碼: IMCR）（"愛文思控股"或"公司"），一家商業階段的生物技術公司，致力於開拓和提供革命性的免疫調節藥物，從根本上改善癌症、傳染病和自身免疫疾病患者的預後，今日宣佈管理層將參加以下投資者會議:
Guggenheim Securities Healthcare Innovation Conference
Fireside Chat: Tuesday, November 12, 2024, at 1:00 p.m. EST
古根海姆證券醫療健康創新會議
爐邊聊天: 2024年11月12日，美國東部時間下午1點
Jefferies London Healthcare Conference
Fireside Chat: Wednesday, November 21, 2024, at 9:00 a.m. GMT
Jefferies倫敦醫療健康會議
爐邊聊天: 2024年11月21日，格林尼治標準時間上午9點
The presentations will be webcast live and can be accessed by visiting 'Events & Presentations', under 'Events', via the 'Investors' section of Immunocore's website at . Following the event, a replay of the presentations will be made available for a limited time.
演示將通過訪問Immunocore網站的「投資者」部分下的「活動」中的「事件與演示」進行網絡直播。活動結束後，演示的回放將在有限時間內提供。
About Immunocore
關於Immunocore
Immunocore is a commercial-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies called ImmTAX – Immune mobilizing monoclonal TCRs Against X disease – designed to treat a broad range of diseases, including cancer, autoimmune, and infectious disease. Leveraging its proprietary, flexible, off-the-shelf ImmTAX platform, Immunocore is developing a deep pipeline in multiple therapeutic areas, including five clinical stage programs in oncology and infectious disease, advanced pre-clinical programs in autoimmune disease and multiple earlier pre-clinical programs. The Company's most advanced oncology TCR therapeutic, KIMMTRAK has been approved for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma in the United States, European Union, Canada, Australia, and the United Kingdom.
Immunocore是一家商業化階段的生物技術公司，致力於開發一種新型的TCR雙特異性免疫療法，稱爲ImmTAX -免疫活化單克隆TCR對抗X疾病 - 旨在治療廣泛的疾病，包括癌症，自身免疫病和傳染病。藉助其專有的、靈活的、現成的ImmTAX平台，Immunocore正在多個治療領域開發深層次的產品線，包括腫瘤學和傳染病的五個臨床階段項目，自身免疫病的先進臨床前項目和多個早期臨床前項目。該公司最先進的腫瘤學TCR療法KIMMTRAk已經在美國，歐盟，加拿大，澳大利亞和英國獲得批准，用於治療HLA-A * 02:01陽性的成年患者無法切除或轉移的葡萄膜黑色素瘤。
Contact Information
聯繫信息
Immunocore
Immunocore
Sébastien Desprez, Head of Communications
T: +44 (0) 7458030732
E: sebastien.desprez@immunocore.com
Follow on Twitter: @Immunocore
Sébastien Desprez，通信部總監
T：+44 (0) 7458030732
電子郵件：sebastien.desprez@immunocore.com
在Twitter上關注：@Immunocore
Investor Relations
投資者關係
Clayton Robertson, Head of Investor Relations
T: +1 (215) 384-4781
E: ir@immunocore.com
投資者關係主管Clayton Robertson
電話：+1（215）384-4781
E: ir@immunocore.com
